SCIENTIFIC ADVISORS

Behind our breakthrough therapeutic solutions is our team of clinical research scientists. Highly collaborative and insightful, they oversee the development of innovative cancer therapies for patients throughout the world who are facing unmet needs.

Click on a team member below to learn more

Lan Huang, Ph.D.

Douglas Blayney, M.D.

Professor of Medicine (Oncology), Stanford University

Patrick Fabbio

Jeffrey Crawford, M.D.

Professor of Medicine, Duke University
Matthew Kirby

Yuankai Shi, M.D.

Associate Dean, Cancer Hospital of Chinese Academy of Medical Sciences
Ramon Mohanlal, M.D., Ph.D.

David Ettinger, M.D.

Professor of Oncology, John Hopkins University
Close

David S. Ettinger, M.D. is the SAB Member for Study 103.

Dr. Ettinger is a Professor of Oncology at Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University. He is also a professor of medicine, otolaryngology, head and neck surgery, gynecology and obstetrics, and radiation oncology and molecular radiation sciences. He is the Chairman of NCCN guideline for NSCLC and Board of Directors of NCCN guideline.

Close

Yuankai Shi, M.D. is the Principal Investigator for Study 105 and Study 106 in China.

Dr. Shi is the Associate Dean and Director of Oncology at Cancer Hospital of Chinese Academy of Medical Sciences and Associate Director of the Chinese Medical Association Hematology Branch. He is the Chairman of the NCCN guidelines for neutropenia management in China.

Close

Jeffrey Crawford, M.D. is the DSMB Chairman for Study 105 and Study 106.

Dr. Crawford is a Professor of Medicine at Duke University. He is the Chairman of NCCN guidelines for neutropenia management in the U.S. and was the lead investigator of the U.S. multicenter, randomized trial of Filgrastim (G-CSF, Neupogen), which received approval from Food and Drug Administration in 1991.

Close

Douglas W. Blayney, M.D. is the Principal Investigator for Study 105 and Study 106.

Dr. Blayney is a Professor of Medicine (Oncology) at Stanford University and former Medical Director of Stanford Cancer Center. He is a founding member and former board member of the NCCN Guidelines for neutropenia management in US, former president of the American Society of Clinical Oncology (ASCO) and has served on the Food and Drug Administration’s Oncologic Drugs Advisory Committee.

Quanqi Song, Ph.D.

Yan Sun, M.D.

Director of GCP Center at Cancer Hospital of Chinese Academy of Medical Sciences
Yanbin Xie, M.D.

Avram Hershko, M.D.

Distinguished Professor at Rappaport Faculty of Medicine at Technion in Haifa

Close

Peony Yu, M.D. is our SAB member.

Dr. Yu is Chief Medical Officer of FibroGen. She has more than 25 years of pharmaceutical leadership, patient care, and drug development experience with deep expertise in all aspects of clinical and regulatory process, and with multiple prior successful NDA/MAAs for novel drugs and drug/device combos. Prior to joining FibroGen, Dr. Yu served as Vice President of Clinical Research at Anesiva Inc. Previously, Dr. Yu was Director of Clinical Development at ALZA Corporation (now Johnson & Johnson); Director of Clinical Development at Pain Therapeutics Inc.; and Assistant Director, Clinical Development, at Elan Corporation plc (now Perrigo Company plc). Earlier in her career, Dr. Yu was Head of the Department of Physical Medicine & Rehabilitation at the Palo Alto Medical Foundation. Dr. Yu received a B.S. in Chemical Engineering from University of California, Davis, and an M.D. from the UC Davis School of Medicine. She completed her residency training at Stanford University School of Medicine. Dr. Yu is a native of China.

Close

Avram Hershko, M.D. is SAB member for the ubiquitination platform.

Dr. Hershko has nearly 50 years of research leadership in ubiquitination pathway. He is laureate of the 2004 Nobel Prize in Chemistry for the discovery of the ubiquitin-mediated protein degradation. He is Distinguished Professor at Rappaport Faculty of Medicine at Technion in Haifa.

Close

Yan Sun, M.D. is the Principal Investigator for Study 103 in China.

Dr. Sun is the Director of GCP Center at Cancer Hospital of Chinese Academy of Medical Sciences. He is the co-founder of the Steering Committee of the Chinese Society of Clinical Oncology (CSCO). He is also the Chairman of the NCCN guidelines for NSCLC in China.

Click on a team member below to learn more

Lan Huang, Ph.D.

Douglas Blayney, M.D.

Professor of Medicine (Oncology), Stanford University
Patrick Fabbio

Jeffrey Crawford, M.D.

Professor of Medicine, Duke University

Close

Douglas W. Blayney, M.D. is the Principal Investigator for Study 105 and Study 106.

Dr. Blayney is a Professor of Medicine (Oncology) at Stanford University and former Medical Director of Stanford Cancer Center. He is a founding member and former board member of the NCCN Guidelines for neutropenia management in US, former president of the American Society of Clinical Oncology (ASCO) and has served on the Food and Drug Administration’s Oncologic Drugs Advisory Committee.

Close

Jeffrey Crawford, M.D. is the DSMB Chairman for Study 105 and Study 106.

Dr. Crawford is a Professor of Medicine at Duke University. He is the Chairman of NCCN guidelines for neutropenia management in the U.S. and was the lead investigator of the U.S. multicenter, randomized trial of Filgrastim (G-CSF, Neupogen), which received approval from Food and Drug Administration in 1991.

Matthew Kirby

Yuankai Shi, M.D.

Associate Dean, Cancer Hospital of Chinese Academy of Medical SciencesAssociate Dean, Cancer Hospital of Chinese Academy of Medical Sciences
Ramon Mohanlal, M.D., Ph.D.

David Ettinger, M.D.

Professor of Oncology, John Hopkins University

Close

Yuankai Shi, M.D. is the Principal Investigator for Study 105 and Study 106 in China.

Dr. Shi is the Associate Dean and Director of Oncology at Cancer Hospital of Chinese Academy of Medical Sciences and Associate Director of the Chinese Medical Association Hematology Branch. He is the Chairman of the NCCN guidelines for neutropenia management in China.

Close

David S. Ettinger, M.D. is the SAB Member for Study 103.

Dr. Ettinger is a Professor of Oncology at Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University. He is also a professor of medicine, otolaryngology, head and neck surgery, gynecology and obstetrics, and radiation oncology and molecular radiation sciences. He is the Chairman of NCCN guideline for NSCLC and Board of Directors of NCCN guideline.

Yanbin Xie, M.D.

Yan Sun, M.D.

Director of GCP Center at Cancer Hospital of Chinese Academy of Medical Sciences
Dan Zabrowski, Ph.D.

Avram Hershko, M.D.

Distinguished Professor at Rappaport Faculty of Medicine at Technion in Haifa

Close

Avram Hershko, M.D. is SAB member for the ubiquitination platform.

Dr. Hershko has nearly 50 years of research leadership in ubiquitination pathway. He is laureate of the 2004 Nobel Prize in Chemistry for the discovery of the ubiquitin-mediated protein degradation. He is Distinguished Professor at Rappaport Faculty of Medicine at Technion in Haifa.

Close

Yan Sun, M.D. is the Principal Investigator for Study 103 in China.

Dr. Sun is the Director of GCP Center at Cancer Hospital of Chinese Academy of Medical Sciences. He is the co-founder of the Steering Committee of the Chinese Society of Clinical Oncology (CSCO). He is also the Chairman of the NCCN guidelines for NSCLC in China.

Close

Peony Yu, M.D. is our SAB member.

Dr. Yu is Chief Medical Officer of FibroGen. She has more than 25 years of pharmaceutical leadership, patient care, and drug development experience with deep expertise in all aspects of clinical and regulatory process, and with multiple prior successful NDA/MAAs for novel drugs and drug/device combos. Prior to joining FibroGen, Dr. Yu served as Vice President of Clinical Research at Anesiva Inc. Previously, Dr. Yu was Director of Clinical Development at ALZA Corporation (now Johnson & Johnson); Director of Clinical Development at Pain Therapeutics Inc.; and Assistant Director, Clinical Development, at Elan Corporation plc (now Perrigo Company plc). Earlier in her career, Dr. Yu was Head of the Department of Physical Medicine & Rehabilitation at the Palo Alto Medical Foundation. Dr. Yu received a B.S. in Chemical Engineering from University of California, Davis, and an M.D. from the UC Davis School of Medicine. She completed her residency training at Stanford University School of Medicine. Dr. Yu is a native of China.

Click on a team member below to learn more

Lan Huang, Ph.D.

Douglas Blayney, M.D.

Professor of Medicine (Oncology), Stanford University

Close

Douglas W. Blayney, M.D. is the Principal Investigator for Study 105 and Study 106.

Dr. Blayney is a Professor of Medicine (Oncology) at Stanford University and former Medical Director of Stanford Cancer Center. He is a founding member and former board member of the NCCN Guidelines for neutropenia management in US, former president of the American Society of Clinical Oncology (ASCO) and has served on the Food and Drug Administration’s Oncologic Drugs Advisory Committee.

Patrick Fabbio

Jeffrey Crawford, M.D.

Professor of Medicine, Duke University

Close

Jeffrey Crawford, M.D. is the DSMB Chairman for Study 105 and Study 106.

Dr. Crawford is a Professor of Medicine at Duke University. He is the Chairman of NCCN guidelines for neutropenia management in the U.S. and was the lead investigator of the U.S. multicenter, randomized trial of Filgrastim (G-CSF, Neupogen), which received approval from Food and Drug Administration in 1991.

Matthew Kirby

Yuankai Shi, M.D.

Associate Dean, Cancer Hospital of Chinese Academy of Medical Sciences

Close

Yuankai Shi, M.D. is the Principal Investigator for Study 105 and Study 106 in China.

Dr. Shi is the Associate Dean and Director of Oncology at Cancer Hospital of Chinese Academy of Medical Sciences and Associate Director of the Chinese Medical Association Hematology Branch. He is the Chairman of the NCCN guidelines for neutropenia management in China.

Ramon Mohanlal, M.D., Ph.D.

David Ettinger, M.D.

Professor of Oncology, John Hopkins University

Close

David S. Ettinger, M.D. is the SAB Member for Study 103.

Dr. Ettinger is a Professor of Oncology at Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University. He is also a professor of medicine, otolaryngology, head and neck surgery, gynecology and obstetrics, and radiation oncology and molecular radiation sciences. He is the Chairman of NCCN guideline for NSCLC and Board of Directors of NCCN guideline.

Quanqi Song, Ph.D.

Yan Sun, M.D.

Director of GCP Center at Cancer Hospital of Chinese Academy of Medical Sciences

Close

Yan Sun, M.D. is the Principal Investigator for Study 103 in China.

Dr. Sun is the Director of GCP Center at Cancer Hospital of Chinese Academy of Medical Sciences. He is the co-founder of the Steering Committee of the Chinese Society of Clinical Oncology (CSCO). He is also the Chairman of the NCCN guidelines for NSCLC in China.

Yanbin Xie, M.D.

Avram Hershko, M.D.

Distinguished Professor at Rappaport Faculty of Medicine at Technion in Haifa

Close

Avram Hershko, M.D. is SAB member for the ubiquitination platform.

Dr. Hershko has nearly 50 years of research leadership in ubiquitination pathway. He is laureate of the 2004 Nobel Prize in Chemistry for the discovery of the ubiquitin-mediated protein degradation. He is Distinguished Professor at Rappaport Faculty of Medicine at Technion in Haifa.

Close
Chief Medical Officer, Fibrogen